Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grant consists of non-qualified stock options to purchase 200,000 shares of common stock at an exercise price of $0.86 per share, which is equal to the closing price of the Company’s common stock on October 13, 2026. The options have a 10-year term and vest over four years, with 25% of the shares vesting on the one-year anniversary of the grant date and the remaining 75% vesting in 36 substantially equal monthly installments thereafter, subject to each respective employee’s continued service with the Company. The inducement grant was outside of the Company’s 2020 Stock Option and Incentive Plan and is subject to the Company’s 2025 Inducement Plan and the applicable award agreement.